Aug 1, 2023
Collaborator: Merck & Co., Inc
We aim to identify molecular pathways potentially involved in the pathophysiology of chronic low back pain and fibromyalgia through the application of metabolomics in thoroughly phenotyped individuals. We aim to discover molecular pathways promoting chronic low back pain and fibromyalgia that would shift the focus of research to the development of target-specific therapeutics, and identify candidate biomarkers.
Michele Curatolo, University of Washington, Seattle (contact)
Daniel Raftery, University of Washington, Seattle